With Nasdaq Medical Claims Insights (NMCI), an exclusive Nasdaq dataset, access one of the most complete views of the US healthcare system, tracking longitudinal and real-time patient journeys of 250+ million unique individuals across HCPs, HCOs, and sites of care. NMCI provides extensive information on patient journeys including details on Rx, specialty pharmaceuticals, clinical records, EHR/EMR, payers, labs, and more. This data is anonymous and does not include any personally identifiable information.

330M+

Patients

9+

Years of Historical Data

70K+

Pharmacies

125K+

Medical Facilities

Whether you are a quantitative hedge fund, a private equity firm exploring the healthcare industry, or a portfolio manager, gain access to new opportunities, insights, and strategies with Nasdaq Medical Claims Insights.

In recent years, there has been significant growth in the GLP-1 treatment sector, with no indications of it slowing down. Utilize NMCI to track this continued growth and observe changes in medication use to help forecast shifts in market share among major manufacturers and players in the healthcare industry.

With NMCI, track transitions across different prescriptions and manufacturers to forecast emerging drugs and shifts in market share. 

• In 2024, 51% of GLP-1 users were new GLP-1 users compared to 2023
• 12% of 2023 GLP-1 users switched from one GLP-1 medication to another in 2024
• 37% of 2023 users continued using the same medication in 2024

Understand the growth in this treatment space to forecast new trends and new investment opportunities

• The first GLP-1 drug was approved by the FDA in 2005
• Ozempic was approved at the end of 2017
• In last few years, we have seen massive growth in this treatment space 
   

Our translation tool strives for accuracy, yet no machine translation is flawless or a substitute for human translators. Translations are offered as a convenience, "as is." We do not guarantee the accuracy, reliability, or correctness of translations from English to other languages. Certain content may not translate accurately due to software limitations.

The original English text prevails on the website. Variances in translation are non-binding and hold no legal weight for compliance or enforcement. For queries about translated content accuracy, consult the official English version of our site.